Eczematoid Dermatitis
Pipeline Programs↗
Active Trials↗
Companies Involved↗
Eczematoid dermatitis is an emerging landscape with 26 programs across 15 companies. The most active players are Sanofi, Kenvue Brands, Pfizer's Upjohn has merged with Mylan to form Viatris Inc.. 17 therapies are approved.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Analysis
Modality Breakdown
85%
Small molecule
22 of 26 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 26 classified programs, each share of the total. Modality classified for 100% of 26 pipeline programs.
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)